These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 23127248)

  • 1. Activin receptor antagonists for cancer-related anemia and bone disease.
    Fields SZ; Parshad S; Anne M; Raftopoulos H; Alexander MJ; Sherman ML; Laadem A; Sung V; Terpos E
    Expert Opin Investig Drugs; 2013 Jan; 22(1):87-101. PubMed ID: 23127248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sotatercept, a soluble activin receptor type 2A IgG-Fc fusion protein for the treatment of anemia and bone loss.
    Raje N; Vallet S
    Curr Opin Mol Ther; 2010 Oct; 12(5):586-97. PubMed ID: 20886391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple-dose, safety, pharmacokinetic, and pharmacodynamic study of sotatercept (ActRIIA-IgG1), a novel erythropoietic agent, in healthy postmenopausal women.
    Sherman ML; Borgstein NG; Mook L; Wilson D; Yang Y; Chen N; Kumar R; Kim K; Laadem A
    J Clin Pharmacol; 2013 Nov; 53(11):1121-30. PubMed ID: 23939631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activin receptor ligand traps in chronic kidney disease.
    Jelkmann W
    Curr Opin Nephrol Hypertens; 2018 Sep; 27(5):351-357. PubMed ID: 29847322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activin receptor signaling: a potential therapeutic target for osteoporosis.
    Lotinun S; Pearsall RS; Horne WC; Baron R
    Curr Mol Pharmacol; 2012 Jun; 5(2):195-204. PubMed ID: 21787285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial.
    Komrokji R; Garcia-Manero G; Ades L; Prebet T; Steensma DP; Jurcic JG; Sekeres MA; Berdeja J; Savona MR; Beyne-Rauzy O; Stamatoullas A; DeZern AE; Delaunay J; Borthakur G; Rifkin R; Boyd TE; Laadem A; Vo B; Zhang J; Puccio-Pick M; Attie KM; Fenaux P; List AF
    Lancet Haematol; 2018 Feb; 5(2):e63-e72. PubMed ID: 29331635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Testing for the erythropoiesis-stimulating agent Sotatercept/ACE-011 (ActRIIA-Fc) in serum by means of Western blotting and LC-HRMS.
    Walpurgis K; Thomas A; Vogel M; Reichel C; Geyer H; Schänzer W; Thevis M
    Drug Test Anal; 2016 Nov; 8(11-12):1152-1161. PubMed ID: 27649383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experimental and investigational therapies for chemotherapy-induced anemia.
    Testa U; Castelli G; Elvira P
    Expert Opin Investig Drugs; 2015; 24(11):1433-45. PubMed ID: 26359222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An activin receptor IIA ligand trap promotes erythropoiesis resulting in a rapid induction of red blood cells and haemoglobin.
    Carrancio S; Markovics J; Wong P; Leisten J; Castiglioni P; Groza MC; Raymon HK; Heise C; Daniel T; Chopra R; Sung V
    Br J Haematol; 2014 Jun; 165(6):870-82. PubMed ID: 24635723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Current approaches in multiple myeloma and other cancer-related bone diseases].
    Engelhardt M; Kleber M; Udi J; Wäsch R
    Dtsch Med Wochenschr; 2012 May; 137(20):1057-61. PubMed ID: 22549292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stromal cell-mediated inhibition of erythropoiesis can be attenuated by Sotatercept (ACE-011), an activin receptor type II ligand trap.
    Iancu-Rubin C; Mosoyan G; Wang J; Kraus T; Sung V; Hoffman R
    Exp Hematol; 2013 Feb; 41(2):155-166.e17. PubMed ID: 23261964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging treatment approaches for myeloma-related bone disease.
    Gavriatopoulou M; Dimopoulos MA; Kastritis E; Terpos E
    Expert Rev Hematol; 2017 Mar; 10(3):217-228. PubMed ID: 28092987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. rHuEPO and improved treatment outcomes: potential modes of action.
    Blackwell K; Gascón P; Sigounas G; Jolliffe L
    Oncologist; 2004; 9 Suppl 5():41-7. PubMed ID: 15591421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sclerostin: a possible target for the management of cancer-induced bone disease.
    Gkotzamanidou M; Dimopoulos MA; Kastritis E; Christoulas D; Moulopoulos LA; Terpos E
    Expert Opin Ther Targets; 2012 Aug; 16(8):761-9. PubMed ID: 22762409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibiting activin-A signaling stimulates bone formation and prevents cancer-induced bone destruction in vivo.
    Chantry AD; Heath D; Mulivor AW; Pearsall S; Baud'huin M; Coulton L; Evans H; Abdul N; Werner ED; Bouxsein ML; Key ML; Seehra J; Arnett TR; Vanderkerken K; Croucher P
    J Bone Miner Res; 2010 Dec; 25(12):2633-46. PubMed ID: 20533325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies.
    Raftopoulos H; Laadem A; Hesketh PJ; Goldschmidt J; Gabrail N; Osborne C; Ali M; Sherman ML; Wang D; Glaspy JA; Puccio-Pick M; Zou J; Crawford J
    Support Care Cancer; 2016 Apr; 24(4):1517-25. PubMed ID: 26370220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EW-7203, a novel small molecule inhibitor of transforming growth factor-β (TGF-β) type I receptor/activin receptor-like kinase-5, blocks TGF-β1-mediated epithelial-to-mesenchymal transition in mammary epithelial cells.
    Park CY; Kim DK; Sheen YY
    Cancer Sci; 2011 Oct; 102(10):1889-96. PubMed ID: 21707864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activin A suppresses neuroblastoma xenograft tumor growth via antimitotic and antiangiogenic mechanisms.
    Panopoulou E; Murphy C; Rasmussen H; Bagli E; Rofstad EK; Fotsis T
    Cancer Res; 2005 Mar; 65(5):1877-86. PubMed ID: 15753386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-beta type I receptor kinase in puromycin-induced nephritis.
    Grygielko ET; Martin WM; Tweed C; Thornton P; Harling J; Brooks DP; Laping NJ
    J Pharmacol Exp Ther; 2005 Jun; 313(3):943-51. PubMed ID: 15769863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigational anabolic therapies for osteoporosis.
    Trivedi R; Goswami R; Chattopadhyay N
    Expert Opin Investig Drugs; 2010 Aug; 19(8):995-1005. PubMed ID: 20629616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.